Articles tagged with Tumor Cells
Researchers at TU Darmstadt found that x-rays trigger a calcium signalling cascade in T-cells, stimulating the immune response. This discovery could lead to improved cancer treatment by enhancing the killing effect of ionising radiation on tumour cells.
A novel inhibitor has been discovered that stalls a critical enzyme inside tumour cells, locking them in place and preventing invasion into healthy tissue. The findings hold promise for the development of metastasis-blocking agents.
Researchers are developing radioconjugate drugs that combine radiation with a tumor-targeting agent to selectively kill cancer cells. Two approved drugs, Lutathera and Pluvicto, demonstrate the potential of this therapy, which could change the future of cancer treatment.
A mutated gene in more than 20% of breast cancer recurrences promotes metastasis and resistance to hormone therapy. Researchers identify potential vulnerabilities, leading to the development of personalized treatment approaches.
Researchers at Gladstone Institutes and UC San Francisco have developed a comprehensive rule book for designing therapeutic cells with improved specificity and safety. The new receptor system, dubbed SNIPRs, is small enough for cost-effective engineering into human cells and can detect and respond to even small amounts of its target. T...
A study from the University of Pittsburgh found that methionine restriction can slow down the growth of difficult-to-treat brain tumors in children, known as diffuse midline gliomas. The researchers discovered that these tumors are uniquely dependent on methionine, an amino acid, and that depleting it can repress cancer cell growth.
Researchers load CAR-T cells with an oncolytic virus to target and kill solid cancer tumors, providing a potent immune response. The combination approach overcomes challenges in treating solid tumors with CAR-T cell therapy alone.
The TTUHSC's C. Patrick Reynolds has received a $1.34 million CPRIT grant to investigate updating the clinical risk stratification scale for neuroblastoma and rhabdomyosarcoma, two childhood cancers in need of improved therapies.
Researchers identified genes and epigenomic marks that enable cancer cells to resist chemotherapy. By inhibiting these marks, epi-drugs can restore treatment sensitivity. Future clinical trials aim to adapt this concept for human use.
Researchers developed a virus that infects cancer cells, killing them while sending signals to nearby uninfected cells for viral attack. This approach shrinks tumors and enhances cancer-killing efficacy in various models, including pancreatic and ovarian cancers.
Researchers developed a new treatment option for relapsed or refractory CD30+ lymphoma using natural killer cells complexed with a CD30/CD16A bispecific antibody. The treatment showed an overall response rate of 89% in patients with advanced lymphoma.
Researchers developed a gel that temporarily houses cytokines and CAR-T cells near tumors, enhancing their attack power. The gel enables continuous release of activated CAR-T cells, effectively treating solid tumors.
Researchers found that bacteria in tumors play a critical role in promoting cancer cell metastasis by modulating the cellular actin network and enhancing cell survival. This discovery could lead to new targets for preventing metastasis, potentially improving cancer treatment outcomes.
Researchers at UC Irvine and IIT develop ALY101, a compound that blocks protein-protein interactions crucial for cancer and rare disease progression. The findings validate a new approach to structure-based drug design, with potential applications in monotherapy or combination regimens.
A new biodegradable gel has been developed to improve the immune system's ability to combat cancer. The gel releases drugs and special antibodies that target tumor cells, slowing their growth and increasing the lifespan of mice. This breakthrough could lead to new clinical trials for human patients in the coming years.
Glioblastomas, the deadliest brain cancer, have evaded immune cells by promoting immunosuppressive myeloid cells. Researchers identified S100A4 as a key molecule that can selectively target these immune suppressive cells. This discovery paves the way for new therapeutic strategies to restore antitumor action in glioblastoma patients.
Dr. Philip D. Greenberg has been elected as the American Association for Cancer Research President-Elect for 2022-2023. He will work to harness advances in cancer research and translate them for patient benefit, with a focus on addressing disparities in minority engagement.
Researchers found that pancreatic cancer cells trigger the breakdown of collagen proteins, which increases arginine levels and signals stellate cells to build fibrotic meshes around tumors. This process, known as desmoplasia, creates a dense environment that promotes aggressive growth and blocks access to therapies.
Scientists have discovered anticancer substances in kudzu roots and soy molasses that can fight cancer, especially when chemotherapy or surgery are dangerous. The isoflavonoids in these plant extracts mimic human estrogen and bind to free radicals, leading to various diseases including cancer formation.
Researchers at CU Anschutz Medical Campus discovered a reactivated protein, Hand2, in certain cases of mesothelioma, which may lead to new treatments. The study aims to investigate the cause and effect of this reactivation.
A new study from the University of Eastern Finland shows that liquid biopsy can detect cancer mutations months before recurrent breast cancer is detected. This method uses biomarkers released by cancer cells in serum samples to assess changes in intratumoural heterogeneity and provide a more accurate clinical picture.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Researchers have identified a new mechanism of action for extracellular vesicles in the development and progression of lymphomas. sPLA2 secreted by tumor-associated macrophages degrades EV-derived phospholipids, enhancing EV function and inducing vital phenomena. This discovery may lead to new drug targets for cancer treatment.
Researchers at the University of Notre Dame have discovered a new pathway for DNA transfer in the tumor microenvironment, which enables cancer cells to share genetic material with other cells. This study sheds light on how cancer spreads and may lead to early detection of different types of tumors.
Researchers at Penn Medicine have discovered a new approach to treat solid cancers using CDH17CAR T cells, which selectively target and eliminate gastrointestinal (GI) solid tumors like gastric, pancreatic, and colorectal cancers in preclinical models. Unlike other immunotherapies, CDH17CAR T cells do not show toxicity to healthy tissues.
Researchers at TTUHSC will investigate common mechanisms of resistance and sensitivity in alternate telomere lengthening (ALT) cancers, with a focus on targeting ATM kinase inhibitors for therapy. The team aims to develop clinical trials for patients with ALT+ cancers.
Researchers at Massachusetts General Hospital discovered that non-dividing colon cancer cells employ Warburg glycolysis to reduce toxic reactive oxygen species accumulation. This adaptation challenges the long-held dogma of the Warburg effect, highlighting the need for single-cell level analysis tools.
Researchers have discovered an essential role of LCOR in enabling cancer cells to present tumour antigens, making them visible to the immune system. This approach increases the success of immunotherapy in triple-negative breast cancer, a subtype with low treatment response rates.
Researchers Miao-Ping Chien and Daan Brinks have developed a method to detect aggressive cancer cells, which can help identify the genetic profile of individual cells and develop targeted medicines. This breakthrough has the potential to improve treatment outcomes for patients with cancer.
A new phenomenon was discovered where increased pressure leads to a sudden burst of rapid and coordinated cellular motion, spraying outwards from the tumour. This fluid-like pushing mechanism can kill cancer cells but also enables them to survive and multiply in new environments.
Researchers identify two genes, GLI1 and Notch1, responsible for aggressive growth and spread of triple negative breast cancers in African American women. A combination approach using inhibitors and chemotherapy agents significantly inhibits tumor growth and metastasis.
Researchers found that hydroxychloroquine inhibits pathways that drive resistance to cisplatin in head and neck cancers, restoring tumor-killing effects. The study paves the way for a clinical trial combining hydroxychloroquine and cisplatin to treat chemotherapy-resistant patients.
Researchers at Karolinska Institutet have found a way to stabilize the cancer-suppressing protein p53 by adding a spider silk protein, creating a more potent variant. This discovery has potential as an approach for cancer therapy.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
Researchers at UNIGE find that near-death experience in primary tumors triggers pro-metastatic states in cells, leading to metastasis. These 'PAME' cells reprogram themselves and trigger a cytokine storm, forming new tumors.
Researchers at Moffitt Cancer Center have developed patient-derived cells that can be used to study leptomeningeal disease, a rare complication of cancer. The cells provide a new opportunity for scientists to understand the disease and identify potential therapeutics.
A U-M study defines how a cytokine and fatty acid combination triggers ferroptosis, a type of cell death previously studied with synthetic molecules. This natural mechanism could make immunotherapy treatments more effective, particularly for cancers where the treatments currently work for only about 30% of patients.
Researchers have found that statins can inhibit the formation of tumors and metastases in animals with increased MACC1 expression. A study analyzing data from over 300,000 patients prescribed statins also showed a correlation between statin use and reduced cancer incidence.
Moffitt researchers have identified key genomic alterations and potential therapeutic targets in transformed cutaneous T-cell lymphoma. The study, which analyzed 56 patient samples, found high tumor mutation burden and UV mutation signatures associated with survival outcomes. The research also uncovered novel therapeutic vulnerabilitie...
A new study found that traditional Chinese medicine Shengmai Yin increases the sensitivity of cancer cells to radiation, reducing radioresistance. By altering DNA methylation status, SMY enhances the efficacy of radiation therapy and reduces side effects.
Researchers at UVA Cancer Center have made a groundbreaking discovery about the EP300 gene and its role in small-cell lung cancer. The study found that the gene makes a protein with properties that can both foster and prevent tumor formation, providing a new potential target for treatment.
Researchers at the University of Helsinki found that a cellular stress state predicts a poor chemotherapy response in ovarian cancer patients. High-stress tumours with an inflammatory microenvironment may resist chemotherapy, making combination therapies a potential solution.
Scientists have developed a new therapy called CINDELA, which employs CRISPR-Cas9 to kill cancer cells while leaving normal tissues intact. The treatment targets specific mutations found in cancer cells and induces cell death through DNA double-strand breaks.
Researchers investigated COVID-19 mortality in adult cancer patients, finding that systemic treatments and comorbidities played a role in increased risk. The study analyzed 2,500 patients and identified specific tumor subtypes associated with higher mortality rates.
A Swiss-French team has identified a mechanism that could lead to the development of new therapies for acute myeloid leukaemia, a particularly dangerous form of cancer. The selective activation of AMPK triggers apoptosis in tumour cells by initiating the cell's stress response.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.
Researchers at the University of Helsinki discovered that tumour cells in ovarian cancer hide from the body's immune system by interacting with specific gene mutations. Tumours with BRCA1/2 mutations are more effectively targeted by killer T-cells, leading to better patient outcomes.
Pulmonary lymphangioleiomyomatosis (LAM) is a rare cancer affecting up to 1 in 1 million women worldwide, characterized by uncontrolled tumor cell growth. Researchers aim to identify new therapeutic targets using extracellular vesicles, with the goal of developing new therapies for LAM patients.
A recent study published in Developmental Cell reveals that Kras mutation causes chromatin rearrangement, leading to stem-like cell regeneration and tumor onset. The team discovered a protein complex called AP-1 as the mediator of this process, which can be targeted with small-molecule drugs.
Researchers have discovered that the tumor suppressor protein pVHL degrades SMAD3, inhibiting the TGF-β signaling pathway and suppressing tumour cell growth. This finding opens up new opportunities for developing cancer therapies by regulating pVHL activity.
Scientists at Technical University of Munich discovered a promising combination therapy for mesenchymal PDAC subtype, showing improved T-cell infiltration and cell cycle arrest when using nintedanib with trametinib. The treatment significantly improves the response of highly aggressive mesenchymal PDAC subtypes in mice.
Researchers have designed a nanoparticle system that can deliver fluorescent dyes to diagnose and treat pancreatic cancer tumors. The system overcomes the challenge of reaching cells deep within dense tumor masses, enabling detailed images of tumor structures and potentially targeted therapies.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
Researchers found that macrophages feed on lactic acid produced by cancer cells, paralyzing killer immune cells and weakening tumour immunity. This discovery highlights the need to curb lactic acid production in tumours to improve immunotherapy outcomes.
Researchers found that hyaluronic acid is not only present in pancreatic tumors but also serves as a nutrient source for cancer cells. This discovery indicates potential new treatments for pancreatic cancer by targeting the sugar scavenging pathway.
Researchers at Northwestern University have developed a novel microfluidic device that can efficiently harvest and sort tumor-eating immune cells from tumors. This technology has shown dramatic results in shrinking tumors in mice compared to traditional methods.
Researchers used optical imaging to study the metabolic interactions between pancreatic cancer cells and surrounding non-cancer cells. They found that cancer cells can hijack the metabolic activity of these non-cancer cells to fuel tumor growth. This discovery could lead to new therapies targeting the tumor microenvironment.
Melanoma cells release small packages containing the protein NGFR, which primes nearby lymph nodes to form new vessels and encourage cancer spread. This process, called lymphangiogenesis, may help doctors determine which patients need more aggressive treatment.
Researchers found that glioma cells with mutated ATRX have reduced Chk1 activity, leading to dysregulated cell cycle and heightened sensitivity to ATM inhibitors. The study suggests that combining radiation therapy with these inhibitors may improve treatment outcomes for patients with this gene mutation.